GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCure Inc (FRA:2US) » Definitions » Other Gross PPE

NextCure (FRA:2US) Other Gross PPE : €9.87 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is NextCure Other Gross PPE?

NextCure's Other Gross PPE for the quarter that ended in Mar. 2024 was €9.87 Mil.

NextCure's quarterly Other Gross PPE increased from Sep. 2023 (€13.49 Mil) to Dec. 2023 (€29.66 Mil) but then declined from Dec. 2023 (€29.66 Mil) to Mar. 2024 (€9.87 Mil).

NextCure's annual Other Gross PPE increased from Dec. 2021 (€22.17 Mil) to Dec. 2022 (€29.83 Mil) but then declined from Dec. 2022 (€29.83 Mil) to Dec. 2023 (€29.66 Mil).


NextCure Other Gross PPE Historical Data

The historical data trend for NextCure's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCure Other Gross PPE Chart

NextCure Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Gross PPE
Get a 7-Day Free Trial 14.46 17.88 22.17 29.83 29.66

NextCure Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.99 14.05 13.49 29.66 9.87

NextCure Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


NextCure (FRA:2US) Business Description

Traded in Other Exchanges
Address
9000 Virginia Manor Road, Suite 200, Beltsville, MD, USA, 20705
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include NC410 a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for LAIR-1 and is designed to block immune suppression mediated by LAIR-1, NC762 a monoclonal antibody that binds specifically to human B7 homolog 4 protein, or B7-H4, a protein expressed on multiple tumor types, and NC525 (LAIR-1 mAb) is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia, or AML, blast cells, and leukemic stem cells, or LSCs.

NextCure (FRA:2US) Headlines

No Headlines